Abstract: The present disclosure relates to theranostic prodrugs with responsive signals in-vitro or in-vivo and uses thereof. It also relates to synthesized europium complexes for evaluating the binding with integrin ?v?3.

Abstract: This invention provides a nucleus-permeable small-molecule inhibitor, L2P4 (where L2 is 4-(4-(Diethylamino)styryl)-N-carboxymethylpyridinium chloride and P4 is an amino acid sequence comprising CAhxYFMVFGGRrRK and they were coupled through amide bond) and synthesis thereof, which effectively targets the dimerization interface of EBNA1, a critical process for the growth of EBVs and the associated tumors. The present invention also provides method of treating and imaging EBV-associated cancers.

Abstract: The present disclosure relates to urinary polyamines useful as prostate cancer biomarkers and a sensitive and specific, method for detecting and quantifying urinary polymaines using lanthanide complexes.

Abstract: This invention is about an improved garage door opener system, with design features for preventing garage door break-in from outside of the garage using an object such as a hanger. Typically, a person pulls down a cord connected to a release handle to release emergency release of a garage door opener, allowing the door to be manually open or closed. An unauthorized person may attempt to pull down the cord using a hanger from outside the garage or to pull or push down the release handle, to open the door from outside and gain unauthorized entrance. The improved garage door opener system provides a mechanism to reverse the pulling direction of the cord and also protects release handle from being accessed from outside the garage, for increased security.

Abstract: The present disclosure relates to urinary polyamines useful as prostate cancer biomarkers. In particular, the present disclosure provides a novel, highly-sensitive and specific, method for detecting and quantifying urinary polyamines using lanthanide complexes or citrate capped gold nanoparticles.

Abstract: The present disclosure relates to theranostic prodrugs with responsive signals in-vitro or in-vivo and uses thereof. It also relates to synthesized europium complexes for evaluating the binding with integrin ?v?3.

Abstract: The present invention provides photopolymer compositions for 3D printing which have low viscosity, proper curing rate, low volume shrinkage, and low ash content. Such compositions may be used in 3D printing for direct investment casting of products and rapid prototyping.

Abstract: The present invention provides photopolymer compositions for 3D printing which have low viscosity, proper curing rate, low volume shrinkage, and low ash content. Such compositions may be used in 3D printing for direct investment casting of products and rapid prototyping.

Abstract: A display system and a method for displaying items and/or performances is provided. At least a display panel is used to play multimedia content. In an embodiment, at least a portion of the display panel turns transparent for displaying items or performances in a display space. In an embodiment, the display item is moved in accordance with the multimedia played on the display panel. In an embodiment, light effects are adjusted during the display. In an embodiment, audio media is played and adjusted during the display.

Abstract: The present invention relates to a new generation of PDT agents based on porphyrin-lanthanide complexes with specific functional groups which can specifically localize on particular tumors, and their PDT processes can be monitored via NIR emission from erbium. In particular, the present invention provides a multi-modal lanthanide-porphyrin PDT agent (Er—R3) that are capable of killing the bladder tumor cells selectivity via 1O2 from porphyrin moiety and affording the fluorescence imaging simultaneously upon Er—R3 binding with the integrin ?v?3 isoform in bladder cancer cells.

Abstract: The present invention relates to a water-soluble, simple, stable tris(N-(tert-butyl)acetamide) cyclen-based europium complex HGEu001 which exhibits the specific subcellular localization in the primary cilium with a quantum yield as high as 10% in water and a lifetime of 0.56 ms lifetime. In particular, the present invention provides simplicity of the design and synthesis of a complex. Comprehensive studies were performed in numerous cell lines, such as HeLa, SN-K-SH and MRC5; the motif structure, HGEu002, has also been synthesized as the negative control for in vitro imaging studies. The two photon in vitro imaging were done in three dimensions to emphasize on the specific localization in primary cilium of HGEu001. This is one of the very limited examples for direct primary cilium imaging.

Abstract: A control system and a method that controls a display system are provided. The control system receives sensing signals from one or more sensors and controls the display of items based on the sensing signals received. In an embodiment, the control system controls at least a display panel that plays multimedia content. In an embodiment, the control system controls the movement of items on display in accordance with the multimedia played on the display panel. In an embodiment, the control system controls lighting effects within a display area containing the item on display during the display. In an embodiment, the control system controls audio media that is played during the display.

Abstract: This invention provides a nucleus-permeable small-molecule inhibitor, L2P4 (where L2 is 4-(4-(Diethylamino)styryl)-N-carboxymethylpyridinium chloride and P4 is an amino acid sequence comprising CAhxYFMVFGGRrRK and they were coupled through amide bond) and synthesis thereof, which effectively targets the dimerization interface of EBNA1, a critical process for the growth of EBVs and the associated tumors. The present invention also provides method of treating and imaging EBV-associated cancers.

Abstract: A display system and a method for displaying items and/or performances is provided. At least a display panel is used to play multimedia content. In an embodiment, at least a portion of the display panel turns transparent for displaying items or performances in a display space. In an embodiment, the display item is moved in accordance with the multimedia played on the display panel. In an embodiment, light effects are adjusted during the display. In an embodiment, audio media is played and adjusted during the display.

Abstract: A memory device may include memory components to store data. The memory device may also include a processor that may decode a codeword associated with the data. The processor may receive the codeword and determine whether the codeword is independently decodable using a BCH decoder. The processor may then decode the codeword using the BCH decoder when the codeword is determined to be independently decodable using the BCH decoder. Otherwise, the processor may decode the codeword using a second decoder and the BCH decoder when the codeword is not determined to be independently decodable using the BCH decoder.

Abstract: A torsion bar includes a housing and at least one inner core. The housing has a receiving space, two opposite fixing grooves defined in a sidewall of the housing and communicating with the receiving space, and a plurality of stripes positioned at an outer surface thereof. The inner core is received in the receiving space, and includes two opposite fixing elements corresponding to the fixing grooves. Each of the fixing elements includes a plurality of first protruding portions located at a side end thereof to facilitate a user to disengage from the housing, and a plurality of second protruding portions located at a surface thereof adjacent to the side end to prevent the inner core from disengaging accidently from the housing. A cross-section of the receiving space is similar to a cross-section of the inner core.

Abstract: A memory device may include memory components to store data. The memory device may also include a processor that may decode a codeword associated with the data. The processor may receive the codeword and determine whether the codeword is independently decodable using a BCH decoder. The processor may then decode the codeword using the BCH decoder when the codeword is determined to be independently decodable using the BCH decoder. Otherwise, the processor may decode the codeword using a second decoder and the BCH decoder when the codeword is not determined to be independently decodable using the BCH decoder.

Abstract: The present invention relates to a new generation of PDT agents based on porphyrin-lanthanide complexes with specific functional groups which can specifically localize on particular tumors, and their PDT processes can be monitored via NIR emission from erbium. In particular, the present invention provides a multi-modal lanthanide-porphyrin PDT agent (Er—R3) that are capable of killing the bladder tumor cells selectivity via 1O2 from porphyrin moiety and affording the fluorescence imaging simultaneously upon Er—R3 binding with the integrin ?v?3 isoform in bladder cancer cells.

Abstract: An abdomen exerciser includes a connecting element, a first roller, a second roller and a holding component. The connecting element includes two connectors and two roller bearings, each connector has a receiving groove, a plurality of locating pores and a plurality of limiting slots. The connectors are connected with the first roller and the second roller respectively. The holding component is received in the receiving grooves. The holding component includes a plurality of ball bearings and a plurality of limiting elements, the ball bearings are locked in the locating pores, the limiting elements are received in the limiting slots.

Abstract: The present invention discloses a new modality of photodynamic therapy (PDT) through the design of the present invention's truly dual-functional—PDT and imaging—gadolinium complex (Gd—N) with a molecular formula of: which can target cancer, cells specifically. The present invention provides a PDT drug that can specifically localize on the anionic cell membrane of cancer cells in which its laser-excited photoemission signal can be monitored without triggering the phototoxic generation of reactive oxygen species—singlet oxygen—prior to due excitation. The present invention also provides the use of Gd—N as a tumor selective PDT photosensitizer modality.